BRCA1 pathway function in basal-like breast cancer cells.
about
Cytotoxic and targeted therapy for hereditary cancersPredictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicinePredictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.SETDB1, HP1 and SUV39 promote repositioning of 53BP1 to extend resection during homologous recombination in G2 cells.High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer.The Fanconi Anemia Pathway Protects Genome Integrity from R-loops.BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanineBRCA1 Is Required for Maintenance of Phospho-Chk1 and G2/M Arrest during DNA Cross-Link Repair in DT40 CellsKaiso depletion attenuates the growth and survival of triple negative breast cancer cellsResveratrol Ameliorates Cardiac Hypertrophy by Down-regulation of miR-155 Through Activation of Breast Cancer Type 1 Susceptibility Protein.BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancerNovel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer.NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?Sensitizing HR-proficient cancers to PARP inhibitors.Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.Immunotherapeutic interventions of Triple Negative Breast Cancer.FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1-defective cells.BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance
P2860
Q26739366-532B51BE-6D6C-4ECE-97B4-BE8429769780Q28072204-759F4ACD-DBEB-47D4-9743-56051817D560Q33441772-A0F25F3E-99E9-4A39-A3E2-46CA9C01DA3AQ35709996-55A31B22-D8E3-4B52-9B7C-2AA460B304D1Q35815004-CDE4B417-1E5A-4377-9D3B-C70E3DA8E7BAQ35846161-937CAA31-7693-4363-B9AD-D71C3B83C51EQ36055075-39143449-1E6C-4232-BAD0-F9F6D28C3FCBQ36174109-7F99AFAC-3164-49F0-81EE-B43D06AEEFE5Q36319385-7E02A673-7930-4CA6-97F0-245AF61C848EQ36831838-A49CB1E2-D0D8-4DD6-A5E0-298946FB839FQ36846719-31D59D1C-728A-4B78-BAAF-658D74C46088Q38725261-1363129B-CFE2-4CF9-A4F0-F01195AE46A6Q39428059-40CAF3C8-D867-483E-97A5-711BD3EB945FQ42371576-8FA70C6B-ED31-4151-87EC-1C92D293E087Q42517340-A492C7F9-DCFE-4094-8A4D-6E45D4B82273Q43898530-823A8887-841D-404A-A547-59EDB54DB053Q48596039-B53BA9AD-6625-457D-9BC5-EEAC1C739D82Q50056096-413425DB-F1CA-43A0-8C5E-4868E63853E7Q52428057-80C571A9-3CC6-4B1D-9178-93C0E9B8B17FQ55230708-F485185A-9F99-49A6-93EE-4A953B111416Q55257180-2F9B6689-ACFE-4450-B9C4-51750715E5C6Q55394676-D1A1B1C0-FCBC-454A-A719-8B78D2CE4AB9Q58696749-68BD9DA0-B2DB-4821-B90F-A8B0F38803A6
P2860
BRCA1 pathway function in basal-like breast cancer cells.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
BRCA1 pathway function in basal-like breast cancer cells.
@ast
BRCA1 pathway function in basal-like breast cancer cells.
@en
BRCA1 pathway function in basal-like breast cancer cells.
@nl
type
label
BRCA1 pathway function in basal-like breast cancer cells.
@ast
BRCA1 pathway function in basal-like breast cancer cells.
@en
BRCA1 pathway function in basal-like breast cancer cells.
@nl
prefLabel
BRCA1 pathway function in basal-like breast cancer cells.
@ast
BRCA1 pathway function in basal-like breast cancer cells.
@en
BRCA1 pathway function in basal-like breast cancer cells.
@nl
P2093
P2860
P356
P1476
BRCA1 pathway function in basal-like breast cancer cells.
@en
P2093
Allison P Clark
Daniel P Silver
David M Livingston
Sarah J Hill
P2860
P304
P356
10.1128/MCB.01646-13
P407
P577
2014-08-04T00:00:00Z